Real-World Effectiveness and Safety of Virulina in Adults with Respiratory and Post-Viral Inflammatory Conditions: A Multicenter Retrospective Cohort Study

Background: Respiratory illnesses are a major contributor to global morbidity. Conventional treatments, though effective, are constrained by adverse effects and incomplete recovery. Virulina, a standardized polyherbal formulation with antiviral and immunomodulatory activity, was evaluated for its real-world effectiveness and safety. Methods: This multicenter, retrospective, post-marketing cohort study analyzed the treatment records of 300 adults (aged 18–65 years) treated with Virulina across five Ayurvedic outpatient clinics in India. Patients received 1 g TID for 14–28 days. The primary outcome was safety, assessed by adverse event incidence. Secondary outcomes included symptom resolution, inflammatory and hematological biomarker changes, and physician-rated vitality scores. Results: Of 300 patients (56% male, mean age 45 years), 70% presented with symptoms, and 54.4% had comorbidities. Virulina therapy yielded marked symptom resolution, with reductions ranging from 75.9% in bronchitis, 78.3% in bronchial asthma, 82.6% in post-viral musculoskeletal symptoms, 84.1% in lung inflammation, to 89.7% in viral respiratory infections (all p < 0.001. Laboratory outcomes showed significant normalization: CRP declined by up to 96.8%, D-dimer by 55%, and leukocyte and eosinophil counts by 48–65% (p < 0.001 for all). Physician-assessed vitality and immune modulation scores improved by 89 - 96%, correlating with clinical recovery. Notably, no adverse events or therapy discontinuations were reported, underscoring an excellent safety profile. Conclusion: Virulina demonstrated substantial symptom improvement, biomarker normalization, and excellent tolerability across a heterogeneous outpatient population with respiratory illnesses. These findings highlight its potential as a safe, accessible adjunct to standard care, meriting validation in prospective randomized controlled trials. Keywords: lower and upper respiratory tract infections, post-viral inflammation, Virulina